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Abstract
Introduction: In the past malaria rapid diagnostic tests (RDTs) for self-diagnosis by travelers were considered suboptimal
due to poor performance. Nowadays RDTs for self-diagnosis are marketed and available through the internet. The present
study assessed RDT products marketed for self-diagnosis for diagnostic accuracy and quality of labeling, content and
instructions for use (IFU).
Methods: Diagnostic accuracy of eight RDT products was assessed with a panel of stored whole blood samples comprising
the four Plasmodium species (n = 90) as well as Plasmodium negative samples (n = 10). IFUs were assessed for quality of
description of procedure and interpretation and for lay-out and readability level. Errors in packaging and content were
recorded.
Results: Two products gave false-positive test lines in 70% and 80% of Plasmodium negative samples, precluding their use.
Of the remaining products, 4/6 had good to excellent sensitivity for the diagnosis of Plasmodium falciparum (98.2%–100.0%)
and Plasmodium vivax (93.3%–100.0%). Sensitivity for Plasmodium ovale and Plasmodium malariae diagnosis was poor
(6.7%–80.0%). All but one product yielded false-positive test lines after reading beyond the recommended reading time.
Problems with labeling (not specifying target antigens (n = 3), and content (desiccant with no humidity indicator (n = 6))
were observed. IFUs had major shortcomings in description of test procedure and interpretation, poor readability and lay-
out and user-unfriendly typography. Strategic issues (e.g. the need for repeat testing and reasons for false-negative tests)
were not addressed in any of the IFUs.
Conclusion: Diagnostic accuracy of RDTs for self-diagnosis was variable, with only 4/8 RDT products being reliable for the
diagnosis of P. falciparum and P. vivax, and none for P. ovale and P. malariae. RDTs for self-diagnosis need improvements in
IFUs (content and user-friendliness), labeling and content before they can be considered for self-diagnosis by the traveler.
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Introduction
In the nineties, malaria rapid diagnostic tests (RDTs) were
suggested for self-diagnosis by travelers [1]. The idea was however
abandoned after several studies had shown poor test performance
and difficulties in interpretation of test results by the ill traveler [1–
4]. Since then, major progresses have been made in RDT design
and performance. Most of the currently marketed RDTs are so-
called one-step RDTs that are more simple and user-friendly [5]
compared to the multi-step RDT products evaluated in previous
studies. Malaria RDTs are now easy to use handheld cassettes
detecting antigens produced by the Plasmodium parasite which
become visible as colored (mostly red) test lines within 20 minutes
[6].
Recently, the decline in malaria burden in many parts of the
world has made stand-by emergency treatment (SBET) more
attractive for many travelers than the classic chemoprophylaxis. In
the SBET strategy, travelers and expatriates to low-resource
endemic settings carry an emergency malaria treatment (with
reliable activity against P. falciparum) for self-administration when
no medical attention is rapidly available. This option may be
considered where the risk of adverse reaction to malaria
chemoprophylaxis outweighs the risk of malaria infection [7,8]
and is increasingly promoted by some experts in travel medicine
[9]. Self-diagnosis of febrile illness with reliable malaria RDTs
could accelerate early therapy (with the standby treatment),
preventing complications and death, or avoid unnecessary use of
antimalarials [10,11].
Nowadays, RDTs for malaria self-diagnosis are available
through the internet, but their diagnostic accuracy and ease of
use have not yet been studied. Also, the quality of instructions for
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use (IFU) – which assure correct performance and interpretation
of the RDT results [4] - can vary widely [12]. Therefore, the
present study assessed both diagnostic accuracy and quality of
packaging, labeling and IFU of RDT products marketed for self-
diagnosis by travelers.
Methods
Ethics Statement
The study was approved by the Institutional Review Board of
ITM and by the Ethical Committee of Antwerp University,
Belgium. RDTs were performed on stored blood samples
(‘‘leftovers’’) obtained as part of routine diagnostic work-up in
international travelers suspected of malaria. In view of the absence
of risk and the anonymous data processing, IRB deemed informed
consent obsolete.
Study Design
RDT products for self-diagnosis were evaluated for diagnostic
accuracy against a panel of 100 stored blood samples obtained in
travelers suspected of malaria and for the quality of packaging and
their IFU.
Patients and Samples
A total of 100 stored EDTA blood samples (including the four
human Plasmodium species as well as malaria negative samples,
Table 1) obtained from returned international travelers clinically
suspected of malaria were selected. Samples were collected
between October 2007 and September 2011 and were stored at
270uC at the Institute of Tropical Medicine (ITM), Antwerp,
Belgium. Species identification was done by expert microscopy,
corrected by four-primer real-time PCR [13].
Malaria Rapid Diagnostic Tests
Availability of RDT products for self-diagnosis on the internet
was assessed using the search engine ‘Google’. The following terms
were used in both English and French: ‘Malaria self-diagnosis’,
‘Malaria self-test’, ‘Malaria survival kit’, ‘Malaria home testing’,
‘Malaria autotest’. Three times a search was performed (January,
April and June 2011). In addition, two manufacturers were
contacted directly for availability of RDT products marketed for
self-diagnosis (Standard Diagnostics and Access Bio Inc.). Another
manufacturer (TODA PHARMA) had contacted himself ITM to
inform that he had RDTs available for self-diagnosis.
Test Procedures
Tests were performed according to the manufacturer’s instruc-
tions, except that a transfer pipette (Finnpipette, Helsinki, Finland)
was used instead of the transfer device supplied with the RDT
products. The first observer was the one who performed the test
and read test results within the specified reading time. The second
observer read test results within 5 additional minutes and was
blinded to the results of the first observer. Both observers were
blinded to the results of microscopy and PCR. The results of the
first observer were considered and compared to the second
observer to determine interobserver agreement. Test lines were
scored for line intensity as described previously [14]. Faint
intensity implies a barely visible test line which risks being
interpreted as negative. In case of absence of the control line, the
result was invalid and considered negative because it was assumed
that travelers will not always have a second RDT available. In
order to assess false positive results occurring upon reading beyond
the recommended reading time (so-called ‘‘back-flow phenome-
non’’ [15], the first observer scored test lines again at the end of
the day, between 2 and 8 hours after initial reading.
RDT Packaging and Instructions for Use
RDTs’ packaging and instructions for use (IFU) were assessed
using a checklist adapted from a previous study [12]. In addition,
typography, lay-out and readability level of the IFUs was assessed
as previously described [12]. Font size was measured in Cicero as
the ‘kp’ distance. For health instructions in general, font sizes .12
are recommended, interline spacing $2 and fonts of open letter
types [16]. The readability level was expressed as Flesh Kincaid
grade level. There are no criteria of readability levels for IFUs but
for patient education files, a level #6th grade is recommended
[16].
Some RDT products (OptiMAL and TODA) were delivered as
boxes containing multiple single-use RDT packages with IFUs
supplied in the boxes as well as in the individual packages. In these
cases only the IFUs included in the individual packages were
considered, as this IFU will most likely be the one available to the
traveler.
Statistical Analysis
For P. falciparum diagnosis, sensitivity was defined as follows: the
number of P. falciparum samples with a visible P. falciparum specific
test line, divided by the total number of P. falciparum samples. For
the non-falciparum species, sensitivity was defined as the number of
non-falciparum samples with a visible pan-pLDH test line, divided
by the total number of non-falciparum samples. As one product
(OneStep, Table 2) detects P. vivax instead of all non-falciparum
species, sensitivity was defined as all P. vivax samples with a visible
P. vivax test line divided by the total number of P. vivax samples.
Sensitivity was calculated with 95% confidence intervals (C.I.).
Table 1. Panel of clinical samples used to assess the test characteristics of the RDT products.
Region of travel
Species
Parasite density/ml median
(range) Africa Asia Caribbean/South-America No data
P. falciparum (n = 55) 2,928 (21–1,750,000) 51 3 1
P. vivax (n = 15) 1,068.5 (15–14,228) 6 6 1 2
P. ovale (n = 15) 817.5 (51–5,930) 14 1
P. malariae (n = 5) 382 (26–1,920) 5 1
Negative for malaria (n = 10) – 8 1 1
doi:10.1371/journal.pone.0053102.t001
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False positive test lines were defined as any visible test line
among the Plasmodium negative samples, non-falciparum samples
generating a visible P. falciparum-specific test line and in addition
for OneStep a visible P. vivax test line generated by P. falciparum, P.
ovale or P. malariae samples.
Inter-observer agreement for positive and negative readings and
line intensity was expressed by kappa values (k). In line with
previous RDT evaluations k 0.60–0.80 was considered good and k
.0.80 excellent.
Blood Lancets and Transfer Devices
The type of blood lancet (e.g. safety lancet with retractable
needle, safety seal lancet, simple lancet) and transfer device
(pipette, straw, loop, inverted cup) was recorded. Besides, blood
lancets were assessed for possibility of reuse. The safety lancets
with retractable needle consist of a plastic casing in which a needle
is fixed. The system has to be primed and next the needle is
launched by pushing on a button. For these systems it was checked
that the needle could not be launched inadvertently (e.g. during
transport in the luggage of the traveler) before the protective cap
was removed.
Additional Analysis
To assess the presence of histidine-rich protein-2 (PfHRP2) in
one P. vivax sample showing a P. falciparum test line of strong and
weak intensity in four and one out of five PfHRP2-detecting
RDTs, a PfHRP2 ELISA (Standard Diagnostics, Hagal-Dong,
Korea) was performed.
Results
RDT Selection
During the internet search eight RDT products were encoun-
tered and ordered. Three of these products were not included in
the final selection: one (Malapack Travel test, http://www.
vaccinations.com.au/product.htm) was not marketed anymore,
the manufacturer of the second product (EZ-Trust Malaria Rapid
Screen Test Kit, CS Innovation Pte Ltd, Singapore) replied not to
start up the production for an order less than 10,000 tests. The
third product that was delivered (Unitest malaria cassette Pf-Pv,
Ciriano global S.L., Zaragoza, Spain) appeared to be an RDT
detecting malaria antibodies instead of antigens (Figure 1),
whereas the product ordered from the manufacturer’s website
clearly mentioned an antigen-detecting product.
In addition to the five ordered RDT products, the three tests
directly provided by the manufacturers (as explained above) were
also included, so that a total of eight RDT products was evaluated
(Table 2). Six RDT formats were cassettes, there was one hybrid
format (OptiMAL) and one RDT (Immunoquick) consisted of a
dipstick.
RDT Performance
The number of samples detected and the number of false
positive lines for malaria negative samples for each RDT product
are displayed in Table 3. For 6/8 RDT products 100% sensitivity
was reached for P. falciparum diagnosis, but Labstix and Onestep
showed false positive lines in respectively 80% and 70% of malaria
negative samples. Three RDT products detected all P. vivax
samples. P. ovale and P. malariae detection was in general poor,
Labstix was the only one diagnosing all samples but this was at the
expense of poor specificity as this product generated visible pan-
pLDH lines in 8/10 Plasmodium negative samples as well.
Cross-reactions of non-falciparum samples with the P. falciparum
test line occurred for the majority of samples in Labstix (94.3%)
and OneStep (80.0%). In addition for OneStep 47 P. falciparum
samples and 12 P. ovale/P. malariae samples showed a visible P. vivax
test line.
Faint Test Lines
For P. falciparum diagnosis, the median percentage of correctly
identified test lines with faint line intensity per RDT product was
3.6% (range 0.0%–14.0%). For the correctly identified non-
falciparum samples, faint line intensities occurred at a median
frequency of 23.8% (range 10%–58.3%).
Interobserver Agreement
Median k for positive/negative readings for the P. falciparum test
line was 0.95 (range 0.50–1.00, OneStep k=0.50), for the non-
falciparum test line this was 0.91 (range 0.66–1.00). For line
intensity readings median k were 0.83 (range 0.70–0.96) and 0.76
(range 0.71–0.85) for the P. falciparum and non-falciparum lines
respectively.
Reading Beyond the Recommended Reading Time
For all but one (SDFK63) products false positive test lines were
seen after reading beyond the recommended reading time among
10.0%–90.0% of the malaria negative samples and 9.4%–100% of
the non-falciparum samples with initially no false positive test lines.
Immunoquick, TODA and Labstix were mainly affected with
nearly half (.44.4%) of malaria negative samples erroneously
diagnosed as malaria and the majority (.88.2%) of non-falciparum
samples diagnosed as P. falciparum malaria upon reading beyond
the recommended time.
RDT Packaging, Content and Design
Half of RDT products assessed had inconsistencies in their
names displayed on the outer packaging, the device packaging and
the IFU. Moreover, 3/8 RDT products did not mention their
target antigens and 2/8 RDT products did not display recom-
mended storage temperature (Table 2). In general, the RDT
products contained all material needed to perform the test,
however to open the buffer vial of Labstix, a scissor was needed
but this was not mentioned among the required materials, only in
the procedural steps of the IFU. Only 2/8 (25.0%) RDT products
contained a correct desiccant – i.e. provided with a color-based
humidity indicator allowing to control for humidity saturation.
Two products did not contain a transfer device, the drop of blood
had to be applied directly to the test strip. The pipettes supplied
with Labstix and OneStep did not contain a mark for indication of
the correct volume of blood.
For 4/7 RDT devices test line labeling consisted of acronyms
(‘Pf’, ‘P’, ‘Pan’), the others used either letters (T) or numbers.
Immunoquick contained no labeling at all as it is a dipstick without
cassette. Incorrect labeling of the reading window was found for
Sanitoets: only the symbols ‘C’ and ‘T’ were displayed at either
side of the reading window while the strip contains a control line
(‘‘C’’) and two test lines. For Labstix discordances were observed
between labeling on the test device (Pf, Pan) and the pictures
displayed in the IFU (T2, T1).
Instructions for Use
OneStep did not deliver an IFU with the tests, nor a link to the
online version. On the website where the product was ordered an
IFU was found. The IFU of OptiMAL consisted only of pictures.
None of the IFUs fulfilled requirements for correct font size (.12),
median font size was 5.0 (range 4.5–9). Only two products used an
interline distance of 2 and six IFUs used an open character.
Malaria Rapid Diagnostic Tests for Self-Diagnosis
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Median Flesh Kincaid grade level was 8.32 (5.86–9.65), only
Immunoquick had a Flesh Kincaid grade level #6th grade.
Shortcomings of the IFU with regard to test procedure and
interpretation are displayed in Table 4. Several critical procedural
steps were missing in more than half of the IFUs. For three RDT
products, the correct use of the blood lancet was not clearly
described or depicted. Sanitoets depicted another type of pipette in
the IFU than was delivered in the kit. Moreover, Sanitoets
mentioned to cut the end of the sealed pipette that contained the
reagent while in the kit a buffer vial with a screw cap was included.
Four IFUs failed to mention that the test should not be read
beyond the recommended reading time and one IFU (TODA) did
Figure 1. Received product of Unitest (Ciriano global S.L., Zaragoza, Spain). The delivered Unitest malaria cassette P.f-P.v kit mentions
detection of antibodies while the almost identical kit on the website mentions detection of the Pf and Pv antigen. (http://www.clinica.co.za/index.
php?page= shop.product_details&flypage= flypage.tpl&product_id= 11&category_id = 3&option= com_virtuemart&Itemid= 90).
doi:10.1371/journal.pone.0053102.g001
Table 3. Test characteristics of the different RDT products.
Number of samples identified (%) False positive lines
P. falciparum P. vivax P. ovale P. malariae
Pv, Po and Pm
(n=35) malaria negative (n=10)
RDT product PD ,1,000/ml
(n = 15)
PD .1,000/ml
(n = 40)
(n = 15) (n = 15) (n = 5) Pf test line Pf test line Pan/Pv test
line
CareStart 15 (100) 40 (100) 15 (100) 4 (26.7) 3 (60.0) 4 (11.4)*
Immunoquick 15 (100) 40 (100) 4 (11.4)
Labstix 15 (100) 40 (100) 15 (100) 15 (100) 15 (100) 33 (94.3)* 8 (80.0) 8 (80.0)
OneStep 15 (100) 40 (100) 12 (80.0) 28 (80.0) 7 (70.0) 3 (30.0)
OptiMAL 11 (73.3) 39 (97.5){ 13 (86.7){ 1 (6.7) 3 (60.0) 2 (5.7) 1 (10.0) 1 (10.0)
Sanitoets 13 (86.7) 39 (97.5){ 12 (80.0)1 7 (46.7) 2 (40.0) 2 (5.7)*
SDFK63 15 (100) 40 (100) 15 (100) 1 (6.7) 3 (60.0) 3 (8.6)*
TODA 15 (100) 40 (100) 14 (93.3) 3 (20.0) 4 (80.0) 1 (2.9)* 1 (10.0)
PD=parasite density, Pf = P. falciparum, Pv = P. vivax, Po = P. ovale, Pm= P. malariae.
*including one P. vivax sample that generated a strong positive result upon testing PfHRP2 ELISA.
{one sample missed with parasite density 2,458/ml.
{including one invalid result. 1 including one missed sample with parasite density 3,251/ml.
doi:10.1371/journal.pone.0053102.t003
Malaria Rapid Diagnostic Tests for Self-Diagnosis
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not display a reading time at all (for this product, information
about reading time was withheld from the box that contained the
single packages used for self-diagnosis).
OneStep did not contain any pictures of possible test results in
the interpretation section. OptiMAL and TODA did not mention
a visible control line and single visible P. falciparum test line as a
possible result. Following their instructions, a P. falciparum infection
always generates both a visible P. falciparum and pan-pLDH test
line. In the present study however, OptiMAL and TODA showed
a single visible P. falciparum test line among one and three P.
falciparum samples respectively, leading to 49/55 (89.0%) and 52/
55 (94.5%) correctly identified P. falciparum samples respectively.
IFUs that did not display all possible combinations for invalid
results generally only depicted a test in which none of the lines
were visible. For TODA, an error was observed on the figure
showing the invalid results, i.e. a cassette was displayed with a
visible control line and an absent test line. Except for Labstix that
depicted a less visible test lines among the positive results, none of
the RDT products mentioned to consider a faint test line as a
positive one. Likewise, causes of false negative and false positive
results were not mentioned. SDFK63 was the single product
mentioning that a negative test does not rule out malaria. Hardly
any advices about test policy were made, except for TODA
mentioning to use the ‘pan’ line for treatment follow-up of a P.
falciparum infection and Labstix and Immunoquick advised to start
treatment in case of a positive test or in case of a negative test and
persistence of symptoms (Table 4).
Table 4. Presence of important items that need to be addressed in the instructions for use.
Procedure section
Care-
Start
Immuno-
quick Labstix OneStep OptiMAL
Sani-
toets SDFK63 TODA
Do not use the RDT if the device
package is damaged
No Yes No Yes No No Yes No
Do not use beyond the expiry date Yes No No Yes No No Yes Yes
Use the device immediately after opening No No No No No Yes Yes No
Place the device on a level surface No N.A No Yes N.A. Yes No Yes
Check the desiccant for signs of exposure
to humidity
No No No No No No No No
Disinfect finger with alcohol wipe Yes Yes Yes Yes No Yes Yes Yes
Allow the finger to dry before pricking No No No Yes No Yes No Yes
Correct use of blood lancet is clearly
described/depicted
No Yes Yes Yes No Yes No Yes
The volume of blood to be transferred is
clearly mentioned
Yes Yes Yes No Yes No Yes No
Hold the buffer vial vertically No No No No No No Yes No
Do not use another buffer than the one
provided in the kit
No No No No No No No No
Use an adequate light source for reading No No No No No No No No
Do not read beyond the recommended
reading time
No Yes Yes Yes No Yes No No
Interpretation section
All possible line combinations for invalid
test results
No No Yes Yes No Yes Yes No
All possible test line combinations for
positive test results
Yes Yes Yes Yes No Yes Yes No
Interpretation of a faint test line as positive No No Yes No No No No No
Causes of false negative results, in
particular low parasitedensities
No No No No No No No No
Causes of false positive results, e.g.
presence of the rheumatoid
factor
No No No No No No No No
A negative test does not rule out malaria No No No No No Yes No No
In case of a negative RDT result and
persistent suspicion ofmalaria repeat the
test after 6–12 h or go to a doctor
No No*{ No* No No No No No
Do not use the test to follow-up treatment No No No No No No No No{
In case of a positive RDT result consult
a doctor
No No* No* No No Yes No No
N.A. = not applicable.
*The user is advised to take the treatment included in the kit.
{Repeating the test after 12 hours is advised, independent of persistence of symptoms.
{The user is advised to use the ‘pan’ line for treatment follow-up.
doi:10.1371/journal.pone.0053102.t004
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Blood Lancets and Transfer Devices
Blood lancets and transfer devices for each RDT product are
depicted in Figure 2. Five lancets were so-called safety lancets with
a retractable needle. For two of them reuse was possible and for
the other three the needle could inadvertently be launched before
removal of the protective cap. Two products did not contain a
transfer device, the drop of blood had to be applied directly to the
test strip. The pipettes supplied with Labstix and OneStep did not
contain a mark for indication of the correct volume of blood.
Discussion
The present study assessed the diagnostic accuracy of malaria
RDT products available for self-diagnosis as well as the quality of
packaging and content, the readability level and lay-out of its IFU.
Sensitivity was variable and for two products an unacceptable high
number of false positive test lines occurred. All but one product
yielded false-positive test lines upon reading beyond the recom-
mended reading time. Major shortcomings in IFU were observed
among all RDT products and the IFUs were not user-friendly.
Limitations and Strengths
The present study used a limited and selected number of
samples, precluding calculation of predictive values and providing
wide confidence intervals for non-falciparum results. Furthermore,
RDTs were performed by trained personnel which allowed
calculation of RDT sensitivity under perfect conditions but the
study design did not include actual performance by the intended
end-user. Likewise, ease of use and potential errors of RDT
performance as well as interpretation by travelers were not
assessed. However, the present study used a collection of samples
comprising all four human Plasmodium species at different parasite
densities providing relevant data on diagnostic accuracy. Besides,
the systematic evaluation of RDT packaging and its IFU allowed
direct comparison between products and assessment of major
shortcomings.
Accuracy for the Diagnosis of Malaria
P. falciparum is the most dangerous species and accurate
diagnosis should be guaranteed, even at low parasite densities
since the non-immune traveler may already have symptoms at
Figure 2. Lancets and transfer devices delivered with the different RDT products. CareStart and OptiMAL included a simple lancet, SDFK63
a safety seal lancet and the other products safety lancets with a retractable needle. The systems of TODA and Immunoquick (SMI) do not require a
transfer device (direct contact of the test strip with the drop of blood). Sanitoets contained a calibrated pipette and OptiMAL a straw pipette. The
other products included a balloon pipette. The transfer devices of OneStep and Labstix did not display a volume mark.
doi:10.1371/journal.pone.0053102.g002
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parasite densities of 100/ml [17]. Six RDT products had a good
sensitivity for P. falciparum diagnosis. The use of Labstix and
OneStep is however precluded due to the unacceptable high
number of false positive test lines. Among the remaining four RDT
products, Immunoquick is less suitable as it only detects P.
falciparum and in most low endemic areas where SBET is
considered P. vivax is prevalent as well. SDFK63, CareStart and
TODA had good sensitivities for both P. falciparum and P. vivax
diagnosis, but detection of P. ovale and P. malariae was poor, which
is a known phenomenon among RDTs [14,18–21]. IFUs should
mention these limitations, and advise to repeat a negative test after
several hours or to seek reliable health care if symptoms persist.
The high number of false positive test lines for Labstix and
OneStep may be due to problems of non-specific binding
including buffer composition [22] and a redesign is needed.
Moreover, the high number of false positive P. vivax test lines for
OneStep may be due to wrong citing of the target antigen which
presumably detects pan-pLDH rather than P. vivax-pLDH, which
has been described previously for other products [23]. The other
false positive test lines occurred at random and may be due to non-
specific reactions [24].
The P. vivax sample showing clearly visible test lines in all
PfHRP2-detecting RDT products was probably obtained from a
patient with a recent P. falciparum infection and PfHRP2
persistence [25] as the presence of PfHRP2 in the blood was
confirmed by ELISA.
Faint test line intensity of true positive test lines occurred mainly
among the non-falciparum species, although for OptiMAL .10%
of P. falciparum samples also generated a faint P. falciparum test line.
Faint test lines are of concern as they tend to be regarded as
negative [26] and will not be visible under unfavorable light
conditions.
It is possible that the ill traveler will check his RDT again after a
few hours to make sure it was really negative. After reading
beyond the recommended reading time, false positive test lines
may occur as demonstrated in the present study, due to the back-
flow phenomenon [15]. Therefore, it is important that the IFU
clearly mentions that reading test results should be performed
within the time specified in the IFU and any test line becoming
visible beyond the recommended reading time should be ignored.
For OneStep even reading a few minutes too late resulted in some
false positive P. falciparum test lines observed by the second
observer and explaining the low interobserver agreement.
RDT Shortcomings in Labeling
The most serious encountered error in labeling was that on the
website of UNITEST malaria antigen detection was clearly
mentioned and displayed on the picture, while the product
delivered targeted malaria antibodies. Apart from errors in the
online ordering system, it is of note that both products are nearly
identical except for differences in the text present on the box
(Figure 1).
RDT Problems in Design
Some observed errors in design may affect performance under
field conditions like errors in labeling of the reading frame and the
need of scissors for opening the buffer vial while not mentioned on
the package or in the IFU. The lack of a mark on the transfer
device to indicate the correct blood volume risks the application of
too much or too little blood, leading to poor background clearance
obscuring the test lines or to false negative results respectively. The
system of direct application of the cassette on the drop of blood
looks attractive, but there are no published data about its
correctness and ease of use. The most accurate, easy to use and
preferred transfer device by health workers in malaria endemic
setting was the inverted cup [27] and it can be assumed that this
will apply to travelers too.
Instructions for Use: Procedure and Interpretation
The presently found shortcomings in the IFU are of concern as
past evaluation showed problems in RDT performance by the ill
traveler which improved after revision of the IFU [4]. None of the
IFUs was written to the level of the end-user (high readability level,
poor lay-out and user unfriendly typography), which is a crucial
requirement for products intended for self-diagnosis [28].
Many of the shortcomings mentioned in Table 4 apply to the
use of RDTs by any end-user and have been observed in products
intended for laboratory use before [12]. Of particular interest to
the layman traveler are to check integrity and expiry date of the
product as it can be assumed that – despite the long shelf-life of
RDTs, storage periods can exceed those indicated by the expiry
dates. Moreover, the traveler, and especially the backpacker, will
not always be able to adhere to storage conditions (for most RDT
products below 30uC) leading to RDT degradation. Further, the
curious traveler might open the RDT packaging before intended
use, particularly when the IFU is included in a single pouch
together with the device, and by doing so he will expose the
product to humidity degradation.
The failure to explain/depict the use of the blood lancet is a
major shortcoming as one of the major difficulties in RDT
performance by travelers observed in previous studies was the
finger prick [2,29]. Test interpretation was another frequently
observed difficulty [2,3] and therefore all possible test results
should preferably be depicted. Of note, information regarding
RDT strategic issues (repeat testing, reasons for false negative tests)
was poor and when available not always correct i.e. using the pan-
pLDH line for treatment follow-up, which is debatable, as also
gametocytes produce pLDH [30,31].
What can be Done to Improve RDTs for Self-diagnosis?
First of all, an accurate performance needs to be assured.
Products like Labstix and OneStep performed insufficiently, they
contained no CE mark but were actually delivered to users in the
European Union. Next, IFUs should give understandable infor-
mation about the product performance, including the limitations
for the diagnosis of the non-falciparum species. Furthermore, the
IFU needs to become more user-friendly and the procedure and
interpretation sections need to be completed at least with the
topics mentioned in Table 4. Also for a traveler, multiple lancets,
transfer devices and alcohol wipes are advised. A tag for
temperature control (i.e. a small device or sticker that changes
color when the maximal temperature has been exceeded) may be
of additional value. Important, fulfillment of all these requirements
does not preclude the need for training and counseling of the end-
user of these tests. Although not presently studied, previous reports
have demonstrated the needs for training and the benefits of a
comprehensive training program [29]. For expatriates and
travelers performing RDTs abroad who ask for advice, we
currently ask them to send a photograph of the RDT. Future
technical developments, such as cell-phone based RDT readers
should be assessed for applications [32].
Conclusion
Diagnostic accuracy of currently on the internet available RDTs
for self-diagnosis is variable. Based on the present study, 3/8 RDT
products are reliable for P. falciparum and P. vivax diagnosis and one
for P. falciparum diagnosis only. Instructions on test performance,
interpretation and limitations and what to do with test results were
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incomplete and unsatisfactory for all RDT products. The presently
observed shortcomings need to be urgently adapted before RDTs
can indeed be used for self-diagnosis by the traveler and
expatriate.
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